Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.
Autor: | Stroik DR; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America., Ceholski DK; Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York City, New York 10029, United States of America., Bidwell PA; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America; Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States of America., Mleczko J; Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York City, New York 10029, United States of America., Thanel PF; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America., Kamdar F; Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States of America., Autry JM; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America., Cornea RL; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America., Thomas DD; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, United States of America. Electronic address: ddt@umn.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of molecular and cellular cardiology [J Mol Cell Cardiol] 2020 Jan; Vol. 138, pp. 59-65. Date of Electronic Publication: 2019 Nov 18. |
DOI: | 10.1016/j.yjmcc.2019.11.147 |
Abstrakt: | There is increasing momentum toward the development of gene therapy for heart failure (HF) that is defined by impaired calcium (Ca 2+ ) transport and reduced contractility. We have used FRET (fluorescence resonance energy transfer) between fluorescently-tagged SERCA2a (the cardiac Ca 2+ pump) and PLB (phospholamban, ventricular peptide inhibitor of SERCA) to test directly the effectiveness of loss-of-inhibition/gain-of-binding (LOI/GOB) PLB mutants (PLB Competing Interests: Declaration of Competing Interest None. (Published by Elsevier Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |